financetom
Business
financetom
/
Business
/
Cocrystal Pharma Q3 loss narrows
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Cocrystal Pharma Q3 loss narrows
Nov 14, 2025 5:32 AM

Overview

* Cocrystal Pharma ( COCP ) Q3 net loss decreases to $2 mln from $4.9 mln yr/yr

* Company received FDA clearance for CDI-988 Phase 1b norovirus study starting Q1 2026

* Company granted NIH SBIR award to advance influenza A/B replication inhibitor program

Outlook

* Company to start Phase 1b norovirus study in Q1 2026

* Company received NIH SBIR award for influenza A/B program

Result Drivers

* Research and development (R&D) expenses for the third quarter of 2025 were $954,000, compared with $3.2 million for the third quarter of 2024

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Net -$2.05

Income mln

Q3 Basic -$0.19

EPS

Q3 $2.09

Operatin mln

g

Expenses

Q3 -$2.09

Operatin mln

g Income

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Cocrystal Pharma Inc ( COCP ) is $8.00, about 87.1% above its November 13 closing price of $1.03

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Copyright 2023-2026 - www.financetom.com All Rights Reserved